A Phase I, Open, Randomised, Non-Comparative, Parallel Group Study of a Potential Cytochrome P450 3A Induction After Repeat Twice Daily Oral Dosing With 100 and 500 mg AZD1981 Tablets for 14 Days to Healthy Male Volunteers With Single Oral Doses of Midazolam 7.5 mg.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 1981; Midazolam
- Indications Anxiety; Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 14 Apr 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 14 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 12 Mar 2009 New trial record